Tags

Type your tag names separated by a space and hit enter

Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
Viruses. 2022 01 14; 14(1)V

Abstract

SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients (n = 53) had partial or complete vaccination schemes with CanSino (45%), Sinovac (19%), Pfizer/BioNTech (15%), and AstraZeneca/Oxford (15%). CanSino was administered most frequently in ambulatory patients (p < 0.01). The control group (n = 19) received no COVID-19 vaccines. Among SARS-CoV-2 variants detected by whole-genome sequencing, VOC Delta B.1.617.2 predominated in vaccinated ambulatory patients (p < 0.01) and AY.4 in hospitalized patients (p = 0.04); VOI Mu B.1.621 was detected in four (7.55%) vaccinated patients. SARS-CoV-2 breakthrough infections in our hospital occurred mostly in patients vaccinated with CanSino due to the higher prevalence of CanSino vaccine administration in our population. These patients developed mild COVID-19 symptoms not requiring hospitalization. The significance of this study lies on the detection of SARS-CoV-2 variants compromising the efficacy of local immunization therapies in Monterrey, Mexico.

Links

Authors+Show Affiliations

Galán-Huerta KA

Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Flores-Treviño S

Department of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Salas-Treviño D

Department of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Bocanegra-Ibarias P

Department of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Rivas-Estilla AM

Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Department of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Lozano-Sepúlveda SA

Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Arellanos-Soto D

Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

Camacho-Ortiz A

Department of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.

MeSH

AdultAgedCOVID-19COVID-19 VaccinesCase-Control StudiesFemaleHospitalizationHospitals, UniversityHumansMaleMexicoMiddle AgedPhylogenyPrevalenceSARS-CoV-2VaccinationVaccine EfficacyWhole Genome Sequencing

Pub Type(s)

Journal Article

Observational Study

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35062359

Citation

Galán-Huerta, Kame A., et al. "Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico." Viruses, vol. 14, no. 1, 2022.

Galán-Huerta KA, Flores-Treviño S, Salas-Treviño D, et al. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. Viruses. 2022;14(1).

Galán-Huerta, K. A., Flores-Treviño, S., Salas-Treviño, D., Bocanegra-Ibarias, P., Rivas-Estilla, A. M., Pérez-Alba, E., Lozano-Sepúlveda, S. A., Arellanos-Soto, D., & Camacho-Ortiz, A. (2022). Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. Viruses, 14(1). https://doi.org/10.3390/v14010154

Galán-Huerta KA, et al. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. Viruses. 2022 01 14;14(1) PubMed PMID: 35062359.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. AU - Galán-Huerta,Kame A, AU - Flores-Treviño,Samantha, AU - Salas-Treviño,Daniel, AU - Bocanegra-Ibarias,Paola, AU - Rivas-Estilla,Ana M, AU - Pérez-Alba,Eduardo, AU - Lozano-Sepúlveda,Sonia A, AU - Arellanos-Soto,Daniel, AU - Camacho-Ortiz,Adrián, Y1 - 2022/01/14/ PY - 2021/11/10/received PY - 2022/01/06/revised PY - 2022/01/11/accepted PY - 2022/1/22/entrez PY - 2022/1/23/pubmed PY - 2022/2/5/medline KW - COVID-19 KW - COVID-19 vaccines KW - CanSino KW - Delta KW - Latin America KW - Mexico KW - Mu KW - SARS-CoV-2 KW - surveillance KW - variant of concern JF - Viruses JO - Viruses VL - 14 IS - 1 N2 - SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients (n = 53) had partial or complete vaccination schemes with CanSino (45%), Sinovac (19%), Pfizer/BioNTech (15%), and AstraZeneca/Oxford (15%). CanSino was administered most frequently in ambulatory patients (p < 0.01). The control group (n = 19) received no COVID-19 vaccines. Among SARS-CoV-2 variants detected by whole-genome sequencing, VOC Delta B.1.617.2 predominated in vaccinated ambulatory patients (p < 0.01) and AY.4 in hospitalized patients (p = 0.04); VOI Mu B.1.621 was detected in four (7.55%) vaccinated patients. SARS-CoV-2 breakthrough infections in our hospital occurred mostly in patients vaccinated with CanSino due to the higher prevalence of CanSino vaccine administration in our population. These patients developed mild COVID-19 symptoms not requiring hospitalization. The significance of this study lies on the detection of SARS-CoV-2 variants compromising the efficacy of local immunization therapies in Monterrey, Mexico. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/35062359/Prevalence_of_SARS_CoV_2_Variants_of_Concern_and_Variants_of_Interest_in_COVID_19_Breakthrough_Infections_in_a_Hospital_in_Monterrey_Mexico_ DB - PRIME DP - Unbound Medicine ER -